Omani experience with the use of factor IX Fc fusion protein

BMJ Case Rep. 2021 Jul 21;14(7):e241154. doi: 10.1136/bcr-2020-241154.

Abstract

We describe our local experience in the management of haemophilia B patients with factor IX Fc fusion protein. Two children with haemophilia B were managed with the use of a personalised/tailored dosing schedule of factor IX Fc fusion protein. Compared with the standard half-life factor IX, prophylaxis with factor IX Fc fusion protein was cost-effective, with much less injections, better bleeding control, improved tolerability or no inhibitor development.

Keywords: congenital disorders; haematology (incl blood transfusion); paediatrics.

Publication types

  • Case Reports

MeSH terms

  • Child
  • Factor IX*
  • Factor VIII
  • Hemophilia B* / drug therapy
  • Humans
  • Immunoglobulin Fc Fragments
  • Recombinant Fusion Proteins

Substances

  • Immunoglobulin Fc Fragments
  • Recombinant Fusion Proteins
  • factor IX Fc fusion protein
  • Factor VIII
  • Factor IX